TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8338988
Drug: Soluble prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble prednisolone + placebo inhalation + terbutaline inhalation
Study: 8338988
Drug: Soluble placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble placebo + budesonide inhalation + terbutaline inhalation
Study: 8338988
Drug: Soluble placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble placebo + placebo inhalation + terbutaline inhalation
Study: 8338988
Drug: Soluble placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble placebo + placebo inhalation + normal saline inhalation
Study: 2424238
Drug: Isotretinoin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (0.5 mg/kg body weight/day for 3 months)
Study: 2424238
Drug: Isotretinoin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (0.75 mg/kg for an additional 3 months)
Study: 2424238
Drug: Isotretinoin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (0.1 or 0 mg/kg during the second 3-month period)
Study: 27017161
Drug: EVARREST™ Fibrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVARREST™ Fibrin Sealant Patch (FP)
Study: 24448120
Drug: OMP 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMP 2.5 mg dexamethasone on 2 consecutive days in a week
Study: 23271912
Drug: Microencapsulated CLA
Normalized name: CLA
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microencapsulated CLA (3 g/day)
Study: 20359146
Drug: Penile injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile injections
Study: 7734010
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 to 40 mg/d)
Study: 3552989
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole Vibrio cholerae vaccine alone
Study: 3552989
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole Vibrio cholerae vaccine with B subunit of cholera toxin
Study: 3552989
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole vibrio plus B subunit vaccine (preliminary data from field efficacy trial)
Study: 3552989
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole vibrio vaccine alone (preliminary data from field efficacy trial)
Study: 24590546
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate injection 25 mg
Study: 24590546
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate injection 100 mg
Study: 24590546
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate injection 150 mg
Study: 22442277
Drug: Vitamin D-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-fortified doogh (DD, containing 500 IU vitamin D(3) and 150 mg calcium/250 ml)
Study: 22442277
Drug: Calcium +
Normalized name: Calcium + D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium + vitamin D(3)-fortified doogh (CDD, containing 500 IU vitamin D(3) and 250 mg calcium/250 ml)
Study: 22442277
Drug: Plain Persian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain Persian yogurt drink or doogh (PD, containing 150 mg calcium and no detectable vitamin D(3)/250 ml)
Study: 12963898
Drug: Lymecycline 300
Normalized name: lymecycline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline 300 mg/day orally plus adapalene gel 0.1%
Study: 12963898
Drug: Lymecycline 300
Normalized name: lymecycline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline 300 mg/day orally plus vehicle gel
Study: 8640382
Drug: Heparin-aspirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-aspirin therapy (Group A)
Study: 8640382
Drug: Both heparin-aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both heparin-aspirin and intermittent compression (Group C)
Study: 1354494
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin 5,000 IU injected into the abdominal wall
Study: 1354494
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin 5,000 IU injected into the shoulder
Study: 6151364
Drug: Atracurium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.6 mg/kg
Study: 26986104
Drug: Sitagliptin/Metformin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin/Metformin combined with low caloric diet (n=115)
Study: 26986104
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine combined with Metformin (n=51)
Study: 22082585
Drug: Argan oil
Normalized name: ARGAN OIL
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argan oil (15 g/d) for 4 weeks
Study: 17429539
Drug: IFN‐alpha 1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha 1b 10MU/m2 three times per week (Tiw) plus lamivudine 3 mg/kg for 6 months
Study: 17429539
Drug: IFN‐alpha 1b
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha 1b 10 MU/m2 three times per week (Tiw) plus HBV vaccine 30 microg once a month
Study: 8695136
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 0.75 mg/kg/min for induction and variable-rate propofol infusion up to 0.15 mg/kg/min for maintenance
Study: 8695136
Drug: Thiopental bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental bolus 2 to 4 mg/kg for induction and isoflurane 0.5% to 1.5% for maintenance
Study: 6360752
Drug: Pivampicillin (Pondocillin)
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (Pondocillin) 500 mg twice daily
Study: 6360752
Drug: Amoxycillin (Amoxil)
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin (Amoxil) 250 mg three times daily
Study: 28222465
Drug: Autologous Conditioned
Normalized name: AUTOLOGOUS CONDITIONED PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Conditioned Plasma (ACP) injection therapy
Study: 28222465
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl) injection therapy
Study: 23566212
Drug: HPβCD diclofenac,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPβCD diclofenac, administered as a small-volume bolus injection every 6 hours for ≥2 days
Study: 10527954
Drug: Urodilatin (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urodilatin (0, 10, 30, or 60 ng/kg/min) combined with inhaled albuterol (200 microg)
Study: 10527954
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (200 microg)
Study: 10527954
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of urodilatin and albuterol
Study: 31888565
Drug: Running therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running therapy (3 times/week for 16 weeks)
Study: 31888565
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (healthy controls)
Study: 30042064
Drug: Vaccine (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (three doses, intramuscular at 0, 1, and 2 months)
Study: 30042064
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three doses, intramuscular at 0, 1, and 2 months)
Study: 25343398
Drug: Two-implant mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant mandibular overdenture (IOD)
Study: 22716205
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health literacy intervention consisting of five culturally sensitive workshops over 12 months.
Study: 15838784
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Azithromycin + Chloroquine)
Study: 17557984
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg + LCD (one meal-replacement shake; two low-calorie meals; total kcal/d approximately 1200-1500)
Study: 17557984
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg + LCD
Study: 15572994
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercises for 1 hour twice weekly for 12 weeks
Study: 15572994
Drug: Physiotherapy exercises
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy exercises focused on improvement of balance for 1 hour twice weekly for 12 weeks
Study: 11507354
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily plus cisapride 20 mg twice daily
Study: 9631925
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (CsA) administered twice daily
Study: 9631925
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (CsA) with concomitant diltiazem administration
Study: 7517238
Drug: H1/H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1/H2 receptor blockers (1 mg/kg ranitidine and 0.1 mg/kg dimetinden) administered 15 min before protamine administration
Study: 4914614
Drug: Methyprylon (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyprylon (300 mg)
Study: 4914614
Drug: Glutethimide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutethimide (500 mg)
Study: 4914614
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (1000 mg)
Study: 31287963
Drug: High-intensity exercise
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity exercise intervention with daily HRV monitoring
Study: 30520964
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (Methotrexate)
Study: 20974593
Drug: Prostaglandin D₂
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin D₂ (PGD₂) infusion at 384 ng/kg/min over 25 min
Study: 20974593
Drug: Prostaglandin D₂
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin D₂ (PGD₂) infusion
Study: 18647212
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care treatment (dietitians with no formal training in behavioural change techniques)
Study: 16234224
Drug: Sildenafil 50
Normalized name: sildenafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 50 mg (4 capsules taken one hour before sexual activity for 2 weeks)
Study: 16234224
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 identical capsules for 2 weeks)
Study: 15127994
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bovine hydroxyapatite (Bio‐Oss) and autogenous bone chips stabilized with Tisseel
Study: 10736385
Drug: Monosodium L-glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium L-glutamate (MSG) 1.5 g/person
Study: 10736385
Drug: Monosodium L-glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium L-glutamate (MSG) 3.0 g/person
Study: 8615394
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg orally thrice daily for 12 days
Study: 1394753
Drug: Caudal injection
Normalized name: LIDOCAINE HYDROCHLORIDE 10 mg in 1 mL INTRACAUDAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal injection of 1.0 ml.kg-1 bupivacaine 0.125% with epinephrine 1:400,000 and fentanyl 1.0 microgram.kg-1 in 1.0 ml of normal saline
Study: 1394753
Drug: Caudal injection
Normalized name: LIDOCAINE HYDROCHLORIDE 10 mg in 1 mL INTRACAUDAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal injection of 1.0 ml.kg-1 bupivacaine 0.125% with epinephrine 1:400,000 and normal saline
Study: 4059300
Drug: Flunitrazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (0.03 mg/kg)
Study: 4059300
Drug: Thiopentone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (5 mg/kg) plus gallamine (0.3 mg/kg)
Study: 29034524
Drug: Intravenous dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dopamine infusion (3 μg kg-1 min-1)
Study: 24835247
Drug: Measles vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles vaccine (MV)
Study: 23224924
Drug: Oral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-citrulline supplementation (3 g/day)
Study: 17986309
Drug: Topical fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical fulvestrant 70 mg mL(‐1) solution
Study: 17986309
Drug: Minoxidil 2%
Normalized name: MINOXIDIL 2% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil 2% solution
Study: 15824848
Drug: Intravenous neridronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous neridronate (2 mg/kg infused IV in 30 minutes every 3 months)
Study: 15824848
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment for the first year)
Study: 15824848
Drug: Intravenous neridronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous neridronate
Study: 7636529
Drug: Schedule 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 1: Etoposide 130 mg/m2/d IV for 3 days and cisplatin 25 mg/m2/d IV for 3 days every 21 days for eight courses.
Study: 7636529
Drug: Schedule 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 2: Etoposide 50 mg/m2/d orally for 21 days and cisplatin 33 mg/m2/d IV for 3 days every 28 days for six courses.
Study: 1964470
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody BW 494
Study: 19839966
Drug: sustained-release dexamphetamine
Normalized name: dextroamphetamine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained-release dexamphetamine (up to 110 mg/day)
Study: 17653683
Drug: Style 410
Approvals — FDA: no, EMA: no, PMDA: no
Description: Style 410 implants (MG)
Study: 17653683
Drug: Vertex implants
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Vortex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertex implants (ES)
Study: 17653683
Drug: Both implants
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both implants (MG and ES)
Study: 16287669
Drug: Sham pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pulsed electromagnetic field treatment (group D)
Study: 10546860
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens of two nucleoside analogues
Study: 10546860
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen including a protease inhibitor
Study: 7721576
Drug: Nitroglycerin applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin applied to the frontotemporal region (5 mg in 2% ointment for 2 hours)
Study: 7721576
Drug: Nitroglycerin applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin applied to the neck, arm, and forearm regions (5 mg in 2% ointment for 2 hours)
Study: 25023094
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment (10 sessions)
Study: 17386166
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus PMR (PMR)
Study: 17386166
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (M)
Study: 7802296
Drug: Esmolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (300 micrograms/kg/min during CPB after a bolus of 2 mg/kg prior to CPB)
Study: 20092882
Drug: Valproate monotherapy
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate monotherapy
Study: 2107762
Drug: Valproate combination
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate combination therapy
Study: 23322666
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 µg/day) for 12 weeks
Study: 21293319
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone acetonide (IVT) 4 mg/0.1 mL
Study: 21293319
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 mL
Study: 18188512
Drug: Citalopram 20-40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20-40 mg daily
Study: 18246740
Drug: Single intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular dose of ceftriaxone (50 mg/kg, not exceeding 1 g)
Study: 18246740
Drug: Five-day azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Five-day azithromycin (10 mg/kg on day 1, then 5 mg/kg daily on days 2-5)
Study: 18246740
Drug: Ten-day amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten-day amoxicillin/clavulanate (90/6.4 mg/kg/day in 2 doses)
Study: 16194624
Drug: Lisuride patches
Normalized name: lisuride
DrugBank: Lisuride (DB00589)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride patches (3mg per patch, 7.0 microg lisuride/h, applied every other day)
Study: 15389177
Drug: High-intensity back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-intensity back school treatment
Study: 15389177
Drug: Low-intensity back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-intensity back school treatment
Study: 11186094
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg of brotizolam (BTZ) administered in the morning
Study: 8622225
Drug: Licensed meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed meningococcal polysaccharide vaccine
Study: 1449049
Drug: oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral midazolam 0.45 mg/kg
Study: 1449049
Drug: oral trimeprazine
Normalized name: trimeprazine
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral trimeprazine tartrate 2 mg/kg, methadone 0.1 mg/kg and droperidol 0.15 mg/kg
Study: 1449049
Drug: intramuscular midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intramuscular midazolam 0.15 mg/kg
Study: 2578469
Drug: 1.2 grams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 grams of aspirin daily
Study: 2578469
Drug: 0.3 grams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 grams of aspirin daily
Study: 24268034
Drug: Probiotics (VSL#3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (VSL#3, 900 × 10^9 daily)
Study: 21972946
Drug: Maximum antiproteinuric
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum antiproteinuric treatment period
Study: 14600073
Drug: 2 microg.kg(‐1).min(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg.kg(‐1).min(‐1) hydrocortisone infusion (II)
Study: 14600073
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrocortisone infusion (II) and GH (III) (IV)
Study: 11726420
Drug: Inhaled milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled milrinone (0.25, 0.5, and 1 mg/mL)
Study: 11726420
Drug: iPGI(2) (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: iPGI(2) (10 microg/mL)
Study: 11726420
Drug: iPGI(2) (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: iPGI(2) (10 microg/mL) + inhaled milrinone (1 mg/mL)
Study: 9221483
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days followed by lansoprazole 30 mg q.d. for 14 days
Study: 9221483
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days followed by omeprazole 20 mg q.d. for 14 days
Study: 9221483
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days
Study: 9221483
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., bismuth-subcitrate 120 mg q.i.d., and lansoprazole 30 mg for 10 days)
Study: 3662908
Drug: Topical epinephrine
Normalized name: epinephrine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical epinephrine (1.25%) applied twice daily
Study: 3662908
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin (0.5%) applied three times daily
Study: 3662908
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin placebo applied three times daily